Dual-histamine receptor blockade with cetirizine - famotidine reduces pulmonary symptoms in COVID-19 patients
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Article activity feed
-
-
SciScore for 10.1101/2020.06.30.20137752: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable In lieu of a placebo control group, for comparison the control(s) consisted of published SOC patient results that were not administered the dual-histamine receptor blockade from the USA, United Kingdom, and China. 2.1 Inclusion and Exclusion Criteria: The inclusion criteria were: (a) Males or females of minimum age of 17; (b) Admission to the hospital with suspected or confirmed pulmonary symptoms of COVID-19. Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not detect open code. Researchers …
SciScore for 10.1101/2020.06.30.20137752: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable In lieu of a placebo control group, for comparison the control(s) consisted of published SOC patient results that were not administered the dual-histamine receptor blockade from the USA, United Kingdom, and China. 2.1 Inclusion and Exclusion Criteria: The inclusion criteria were: (a) Males or females of minimum age of 17; (b) Admission to the hospital with suspected or confirmed pulmonary symptoms of COVID-19. Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:4.4 Limitations: There are multiple limitations to any physician-sponsored cohort (or case series) study. Within this initial study the limitations were most notably: (a) This proof-of-principle study was not a placebo-controlled, randomized, and blinded study that is customary for a regulatory registration trial; and (b) The study lacked a sufficiently high number of untreated SOC patients for use as a retrospective control cohort. However, the investigators have provided comparisons to the published SOC cohorts from other regions in the USA, UK, and China. However, offsetting these limitations it should be noted that this work was performed in April through June 2020 during an intense season within the COVID-19 pandemic crisis, at a time-is-of-the-essence season when pulmonologists, emergency room physicians, critical care specialists, and hospitalists were eager to attempt rational repurposing of previously FDA-approved medications. Thus, the physicians desired near-term improved outcomes, compassionate care, and to identify new proof-of-concept off-label therapies for COVID-19 ARDS or ARDS-like patients. Cetirizine and famotidine were intentionally incorporated into treatment of this severe and critical patient cohort in view of exceptional historic safety of each medication, as evidenced by their approved OTC status, and in view of prior efficacy of dual-histamine receptor blockade in diseases in humans and animal models. This resulted in the vast majority of all COVID-1...
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- No funding statement was detected.
- No protocol registration statement was detected.
-
